PEOPLE - Changes at VenPro:
This article was originally published in Clinica
Executive Summary
Rob Michiels has resigned from his dual position as president and chief operating officer of Interventional Technologies and managing director of the US cardiovascular device company's European subsidiary to join the California-based life sciences company VenPro. Other organisational changes within the company include Dr William Crawford retiring in August as vice-president of medical and regulatory affairs; and the promotion of Michael Klicpera to vice-president of legal and regulatory affairs, Dolf Meewis to vice-president of international sales and marketing and Ed Pannek to managing director of Interventional Technologies Europe.
You may also be interested in...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.